Last reviewed · How we verify
Anticoagulant treatment Rivaroxaban
Rivaroxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation.
Rivaroxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis (DVT) prevention and treatment, Pulmonary embolism (PE) prevention and treatment.
At a glance
| Generic name | Anticoagulant treatment Rivaroxaban |
|---|---|
| Sponsor | Rennes University Hospital |
| Drug class | Direct Factor Xa inhibitor |
| Target | Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Rivaroxaban selectively inhibits Factor Xa, a key enzyme in the intrinsic and extrinsic coagulation pathways. By blocking Factor Xa, it prevents the conversion of prothrombin to thrombin, thereby reducing thrombin generation and inhibiting clot formation. This oral anticoagulant is used to prevent and treat thromboembolism in various clinical settings.
Approved indications
- Atrial fibrillation for stroke prevention
- Deep vein thrombosis (DVT) prevention and treatment
- Pulmonary embolism (PE) prevention and treatment
- Acute coronary syndrome
Common side effects
- Bleeding
- Dyspepsia
- Abdominal pain
- Nausea
Key clinical trials
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants) (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
- Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves (PHASE3)
- Anticoagulation in Patients With Venous Thromboembolism and Cancer
- High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anticoagulant treatment Rivaroxaban CI brief — competitive landscape report
- Anticoagulant treatment Rivaroxaban updates RSS · CI watch RSS
- Rennes University Hospital portfolio CI